Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: A report of 5 cases

Wiener Klinische Wochenschrift

Volumn 125, Issue 11-12, 2013, Pages 328-333

  Kronbichler, Andreas ^a   König, Paul ^a   Busch, Martin ^b   Wolf, Gunter ^b   Mayer, Gert ^a   Rudnicki, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Adult nephrotic syndrome; Focal segmental glomerulosclerosis; Minimal change disease; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; ADULT DISEASE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; RECURRENCE; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879688995     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0366-7     Document Type: Article

References (28)

1. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445-53.
2. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169-77.
3. Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol. 2001;21(1):28-34.
4. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4(10):550-9.
5. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome study group. Kidney Int. 1999;56(6):2220-6.
6. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002;17(11):2011-13.
7. Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2006;21(2):201-5.
8. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910-5.
9. Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25(3):461-8.
10. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal chang. disease. Clin Nephrol. 2011;76(2):151-8.
11. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207-12.
12. Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin Pract. 2012;120(2):c79-85.
13. Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317-23.
14. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98-105.
15. Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med. 2012;51(7):759-62.
16. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239-48.
17. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosi: report of four cases and review of the literature. Neth J Med. 2008;66(10):408-15.
18. Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008;23(1):377-80.
19. Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49(1):158-61.
20. Beco A, Castro-Ferreira I, Coentrao L, Neto R, Sampaio S, Pestana M. Rituximab for steroid-dependent nephrotic syndrome. Clin Nephrol. 2010;74(4):308-10.
21. Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med. 2009;48(21):1901-04.
22. Amemiya N, Takei T, Kojima C, Nokiba H, Itabashi M, Nitta K. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol. 2011;15(6):933-6.
23. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009;44(9):922-34.
24. Datta SK. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol. 2009;5(2):80-2.
25. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.
26. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20 + T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563-71.
27. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009;76(5):487-91.
28. Kanai T, Shiraishi H, Yamagata T, Ito T, Odaka J, Saito T, et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. Clin Exp Nephrol. 2010;14(6):578-83.